MolecuLight Analysis: $54M Raised
What is MolecuLight?
MolecuLight offers handheld fluorescence imaging devices for point-of-care detection of wounds with elevated bacterial burden >10^4 CFU/g. The i:X and DX systems provide real-time, non-invasive imaging and digital wound measurement. Devices are FDA and CE cleared, with EHR integration and thermal imaging available on the DX model. Clinical studies show 79% greater wound area reduction and 2x faster healing when bacterial hotspots are removed.
Location
Toronto, Canada
Employees
51-200
Founded
2013
Funding Status
Series A
Product Features & Capabilities
- MolecuLight i:X fluorescence imaging system
- MolecuLight DX fluorescence imaging system with thermal imaging
- DarkDrape accessory
- WoundStickers accessory
- i:X Sterile Surgical Sleeve
- EHR integration
- Auto Depth wound measurement
Use Cases
Detect bacterial hotspots in diabetic foot ulcers; Measure wound area and depth digitally without patient contact; Monitor wound progression over time; Identify infections across all skin tones; Remove bacterial hotspots to reduce wound size by 79% by 12 weeks; Improve healing rates by 2x using MolecuLight-informed care; Reduce antimicrobial dressing expenditure
Other Considerations
FDA and CE cleared; EHR integrated with leading platforms; 79% greater wound area reduction in clinical studies; 2x more wounds healed by 12 weeks vs. standard care; Designated as Innovative Technology by Vizient; Included in ISWCAP Consensus Guidelines; Awarded Premier’s Technology Breakthrough Designation
See something that needs updating? Suggest edits to this profile.